complement-c5

Complement C5-IN-1 is a small-molecule inhibitor of complement component 5 protein (C5).

Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds to human complement protein C5 with high affinity, targeting complement factor 5 to block complement activation. It can be used for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis.

Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5

Anti-Complement C5aR1 Antibody is an antagonistic monoclonal antibody targeting C5a receptor 1 (C5aR1). It inhibits downstream chemotaxis and inflammatory responses by neutralizing C5a-receptor interaction.

Zilucoplan(PEG2) is a derivative of Zilucoplan where the linker component has been substituted with PEG2 instead of PEG24. This compound acts as an effective inhibitor of complement component 5 (C5).

Cemdisiran, an investigational N-acetylgalactosamine-conjugated RNAi (RNA interference) agent with terminal sugar modification, is a small interfering RNA (siRNA) designed to specifically target and suppress the C5 mRNA, thereby reducing the liver's production of the complement component C5 [1].

ARC1905, a non-PEGylated/naked anti-C5 RNA aptamer, functions by inhibiting the cleavage of complement factor 5 (C5) into its components, C5a and C5b, without PEG conjugation. This compound is currently being researched for its potential application in the treatment of age-related macular degeneration (AMD).

ARC186 is a highly potent aptamer that serves as a complement inhibitor by blocking the convertase-catalyzed activation of C5.

Zilucoplan (RA101495), a 15-amino acid macrocyclic peptide and potent complement component 5 (C5) inhibitor, is used in the study of immune-mediated necrotising myopathy (IMNM) [1] [2].

Gefurulimab (ALXN-1720) is a human-derived bispecific antibody that targets complement C5 and albumin, specifically binding to C5 to inhibit its activation [1].

Pexelizumab (h5G1.1-SC), a humanized scFv monoclonal antibody, targets the C5 complement component, thereby inhibiting apoptosis and leukocyte infiltration. It is utilized in researching cerebral ischemia-reperfusion (IR) injury and myocardial infarction [1] [2].

Crovalimab (SKY59; RO7112689) is an Fc-engineered and pH-dependent humanised monoclonal antibody that binds to complement C5 and blocks its cleavage into C5a and C5b, thereby inhibiting MAC formation and intravascular haemolysis. It can rebind to the FcRn receptor under acidic pH conditions and return to the bloodstream, making it suitable for the treatment of paroxysmal nocturnal haemoglobinuria (PNH).

NH2-C6-ARC186 is a derivative of the aptamer ARC186, featuring an NH2-C6 moiety that enables coupling to various peptides or molecules. As a potent complement inhibitor, it operates by inhibiting convertase-mediated C5 activation [1].

Zilucoplan TFA (RA101495), a 15-amino acid macrocyclic peptide, is a potent inhibitor of complement component 5 (C5) with applications in studying immune-mediated necrotising myopathy (IMNM) [1] [2].

Anti-Complement Factor P/Properdin Antibody is a specialized monoclonal antibody target the human properdin protein with high affinity and selectivity, inhibition of the alternative complement pathway activation by disrupting the stabilization of the C3 and C5 convertase complexes across various preclinical experimental models.

Ascuprubart is an antibody targeting Complement C5 and can be used for life science research.

Vensobafusp alfa (KP-104) is a fusion protein composed of an IgG4 monoclonal antibody targeting complement protein C5, combined with the domains 1-5 of complement factor H (FH1-5). It exhibits anti-inflammatory and immunomodulatory properties. The isotype control for Vensobafusp alfa can be referred to as human IgG4(S228P) kappa.

Boc-Leu-Gly-Arg-AMC is a specific fluorogenic substrate designed for the enzymatic detection and quantification of complement component C3/C5 convertases, coagulation factor Xa, and soybean trypsin-like enzyme activity. Boc-Leu-Gly-Arg-AMC is also susceptible to hydrolysis by macropain, a high molecular weight thiol proteinase isolated from human erythrocytes, making it a versatile tool for enzymatic assays.

C5 Protein (human) is a naturally glycosylated polypeptide composed of two disulfide-linked chains. It is essential for the formation of the membrane attack complex (MAC) and is activated via all three pathways of complement activation.